14. Kanodia KV, Vanikar AV, Nigam L, Patel RD, Suthar KS, Patel H. Clinicopathological study of nondiabetic renal disease in type 2 diabetic patients: A single center experience from India. Saudi Journal of Kidney Disease and Transplantation. 2017; 28(6): 1330-1337. DOI: 10.4103/1319-2442.220877
15. Wu D, Xuan Y, Ruan Y, Feng X, Zhu Y, Jia, Liu J, Li H, Li L, Dong X. Prevalence of macro- and microvascular complications in patients with type 2 diabetes and kidney disease with or without albuminuria in a single Chinese Diabetes Centre. Diabetes and Vascular Disease Research. 2016;13(1):21-30. DOI: 10.1177/1479164115610247
16. Low SK, Sum CF, Yeoh LY, Tavintharan S, Ng XW, Lee SB, Tang WE, Lim SC. Prevalence of Chronic Kidney Disease in Adults with Type 2 Diabetes Mellitus. Annals Academy of Medicine Singapore. 2015;44(5):164-71.
17. Fouad M, Fathy H, Zidan A. Serum uric acid and its association with hypertension, early nephropathy and chronic kidney disease in type 2 diabetic patients. The Brazilian Journal of Nephrology. 2016;38(4):403-410. DOI: 10.5935/0101-2800.20160065
18. Penno G, Solini A, Zoppini G, Fondelli C, Trevisan R, Vedovato M, Cavalot F, Gruden G, Lamacchia O, Lavio- la L, Orsi E, Pugliese G. Independent correlates of urinary albumin excretion within the normoalbuminuric range in patients with type 2 diabetes: The Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicentre Study. Acta Diabetologica. 2015; 52(5):971-81. DOI: 10.1007/ s00592-015-0789-x
19. Penno G, Solini A, Zoppini G, Fondelli C, Trevisan R, Vedovato M, Gruden G, Lamacchia O, Pontiroli AE, Arosio M, Orsi E, Pugliese G. Hypertriglyceridemia Is Independently Associated with Renal, but Not Retinal Complications in Subjects with Type 2 Diabetes: A Cross-Sectional Analysis of the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study. PLoS One. 2015;10(5):125-512. DOI: 10.1371/journal.pone.0125512
20. Salinero-Fort MД, San Andres-Rebollo FJ, de Burgos-Lunar C, Abanades-Herranz JC, Carrillo-de-San- ta-Pau E, Chico-Moraleja RM, Jimenez-Garcia R, Lopez- de-Andres A, Gomez-Campelo P Cardiovascular and all-cause mortality in patients with type 2 diabetes mellitus in the MADIABETES Cohort Study: Association with chronic kidney disease. Journal of Diabetes and its Complications. 2016;30(2):227-36. DOI: 10.1016/j.jdia- comp.2015.10.007
21. Какорин СВ, Искандарян РА, Мкртумян АМ. Контроль гликемии и сахароснижающая терапия у больных сахарным диабетом 2 типа с сердечно-сосудистыми заболеваниями (обзор многоцентровых рандомизированных клинических исследований). Сахарный диабет. 2016; 19(3):221 -228. [Kokorin SV, Iskandaryan RA, Mkrtumyan AM. Glycemia Control and hypoglycemic therapy in patients with type 2 diabetes mellitus with cardiovascular diseases (review of multicenter randomized clinical trials). Saharnij Diabet. 2016;19(3):221-228. (In Russian)]
22. Kanasaki K. The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin. Clinical Science. 2018;132(4):489-507. DOI: 10.1042/CS20180031
23. Coppolino G, Leporini C, Rivoli L, Ursini F, di Pao- la ED, Cernaro V, Arturi F, Bolignano D, Russo E, De Sar- ro G, Andreucci M. Exploring the effects of DPP-4 inhibitors on the kidney from the bench to clinical trials. Pharmacological Research. 2018;(129):274-294. DOI: 10.1016/j. phrs.2017.12.001
24. Шестакова МВ, Шамхалова МШ. Сахарный диабет и патология почек: преимущества терапии, основанной на инкретинах. Consilium Medicum. 2013;(4): 10-14 [Shestakova MV, Shamkhalova MSh. Diabetes mellitus and kidney disease: benefits of hormone-based therapy. Consilium Medicum. 2013;(4):10-14. (In Russian)]
25. Корбут АИ, Климонтов ВВ. Терапия, основанная на инкретинах: почечные эффекты. Сахарный диабет. 2016; 19(1):53-63. [Korbut AI, Klimontov VV. Hormone-based Therapy: renal effects. Saharnij Dia- bet.2016;19(1):53-63. (In Russian)]
26. Салухов ВВ, Демидова ТЮ. Эмпаглифлозин как новая стратегия управления исходами у пациентов с сахарным диабетом 2 типа и высоким кардиоваскулярным риском. Сахарный диабет. 2016; 19(6):494- 510. [Salukhov VV, Demidova TYu. Empagliflozin as a new strategy of outcome management in patients with type 2 diabetes mellitus and high cardiovascular risk. Saharnij Diabet. 2016;19(6):494-510. (In Russian)]
27. Резолюция промежуточного совещания экспертного совета по результатам исследования EMPA- REG OUTCOME. Сахарный диабет. 2016;19(2):181- 184. [Resolution of the interim meeting of the expert Council on the results of the study EMPA-REG OUTCOME). Saharnij Diabet. 2016; 19(2): 181 -184. (In Russian)] DOI: 10.14341 / DM2004126-29
28. Дедов ИИ, Шестакова МВ, Аметов АС, Анциферов МБ, Галстян ГР, Майоров АЮ, Мкртумян АМ, Петунина НА, Сухарева ОЮ. Инициация интенсификация сахароснижающей терапии у больных сахарным диабетом 2 типа: обновление консенсуса совета экспертов Российской ассоциации эндокринологов (2015 г.). Сахарный диабет. 2015;(1):5-23. [Dedov II, Shestakova MV, Ametov AS, Antsiferov MB, Galstyan GP, Mayorov AYu, Mkrtumyan AM, Petunina N, Sukhareva OYu. Initiation and intensification of hypoglycemic therapy in patients with type 2 diabetes: update of consensus of the Council of experts of the Russian Association of endocrinologists (2015). Saharnij Diabet. 2015;(1):5-23. (In Russian)]
29. Lv J, Ehteshami P, Sarnak MJ, Tighiouart H, Jun M, Ninomiya T, Foote C, Rodgers A, Zhang H, Wang H, Strippoli GF, Perkovic V Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. Canadian Medical Association. 2013;185(11):949-57. DOI: 10.1503/ cmaj.121468
30. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman JM, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner 2, Riccard G, Taskinen M, Tokgozoglu L, Verschuren W, Vlachopoulos C, Wood DA, Zamorano JL, Cooney M. Рекомендации ЕОК/ ЕОА по диагностике и лечению дислипидемий 2016. Российский кардиологический журнал. 2017;(5):7-77. [Catapano AL, Graham I, De Backer G, Wiklund O, Chapman JM, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner 2, Riccard G, Taskinen M, Tokgozoglu L, Verschuren W, Vlachopoulos C, Wood DA, Zamorano JL, Cooney M. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Russian Journal of Cardiology. 2017;(5):7-77. (In Russian)]
31. Corcillo A, Pivin E, Lalubin F, Pitteloud N, Burnier M, Zanchi A. Glycaemic, blood pressure and lipid goal attainment and chronic kidney disease stage of type 2dia- betic patients treated in primary care practices. Swiss Medical Weekly. 2017;(11):144-59. DOI: 10.4414/smw.2017. 14459